Inhibitory effect and molecular mechanism of mesenchymal stem cells on NSCLC cells

Mengwu Pan1, Lingling Hou2, Jingsi Zhang1

  • 1College of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, 100044, People's Republic of China.

Insights

Mesenchymal stem cells (MSCs) inhibit non-small-cell lung cancer (NSCLC) growth and migration. MSCs secrete factors, including VEGF, that suppress tumor cell proliferation and migration via the MAPK/eIF4E pathway, offering a novel cancer therapy strategy.

Area of Science:

  • Oncology
  • Stem Cell Biology
  • Molecular Biology

Background:

  • Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer mortality with limited treatment options.
  • Mesenchymal stem cells (MSCs) show promise in cancer therapy due to their tumor-homing and immunosuppressive properties.
  • MSCs secrete trophic factors that influence tumor cell behavior.

Purpose of the Study:

  • To investigate the therapeutic potential of mesenchymal stem cells (MSCs) in non-small-cell lung cancer (NSCLC).
  • To elucidate the mechanisms by which MSCs affect NSCLC cell proliferation and migration.

Main Methods:

  • Co-culture systems and conditioned medium experiments with NSCLC cell lines (A549, NCI-H460, SK-MES-1).
  • Scratch assays to assess cell migration.
  • Western blot analysis to evaluate protein expression.
  • Human Gene Expression Microarray Assay and VEGF165 neutralization experiments.

Main Results:

  • MSC-secreted factors inhibited NSCLC cell proliferation and migration in vitro.
  • Expression of proteins involved in proliferation, anti-apoptosis, and migration was decreased via the MAPK/eIF4E signaling pathway.
  • Vascular Endothelial Growth Factor (VEGF) was identified as a key factor mediating these effects by suppressing translation initiation factor eIF4E.

Conclusions:

  • MSCs exert anti-tumor effects on NSCLC through paracrine signaling.
  • VEGF secreted by MSCs plays a crucial role in inhibiting NSCLC progression by modulating the MAPK/eIF4E pathway.
  • MSC-derived trophic factors represent a potential novel therapeutic strategy for NSCLC.